Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Immunotherapy plus chemotherapy improved overall survival in people with persistent, recurrent or metastatic cervical cancer.
Imfinzi plus chemotherapy led to a modest but significant improvement in overall survival.
Data from early clinical trials suggest new precision cancer treatments are on the horizon.
Adding Zytiga plus prednisolone to standard therapy lengthened survival.
The antibody-drug conjugate Tivdak led to remission in 24% of cervical cancer patients.
Third booster dose may improve immune response in cancer patients without sufficient protection after second dose.
Keytruda plus chemotherapy reduced the risk of death by 27% in people with locally advanced or metastatic disease.
Adding the CDK 4/6 inhibitor to hormone prolonged survival by a year.
Opdivo plus relatlimab delayed disease progression compared with Opdivo alone.
A large number of cancer survivors still suffer from significant health issues years after being declared disease-free.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.